Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato

Carlos Aguiar; Eduardo Alegría; Ricardo C. Bonnadonna; Alberico L. Catapano; Francesco Consentido; Moses Elisaf; Michel Farnier; Jean Fierrières; Pasquale Perronre Filardi; Nicolae Hancu; Meral Kayikcioglu; Alberto Mello e Silva; Jesús Millán; Zeljko Reiner; Lale Tokgozoglu; Paul Valensi; Margas Viigimaa; Michal Vrablik; Alberto Zambón; José Luis Zamorano; Roberto Ferrari; Mariano Blasco; Ángel Brea; Ángel Díaz; Pedro Gonzáles Santos; Antonio Hernández Mijares; Teresa Mantilla; Juan Pedro-Botet; Xavier Pintó

doi:10.1016/j.arteri.2015.12.001

Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato

Carlos Aguiar
, Eduardo Alegría
, Ricardo C. Bonnadonna
, Alberico L. Catapano
, Francesco Consentido
, Moses Elisaf
, Michel Farnier
, Jean Fierrières
, Pasquale Perronre Filardi
, Nicolae Hancu
, Meral Kayikcioglu
, Alberto Mello e Silva
, Jesús Millán
, Zeljko Reiner
, Lale Tokgozoglu
, Paul Valensi
, Margas Viigimaa
, Michal Vrablik
, Alberto Zambón
, José Luis Zamorano

Roberto Ferrari, Mariano Blasco, Ángel Brea, Ángel Díaz, Pedro Gonzáles Santos, Antonio Hernández Mijares, Teresa Mantilla, Juan Pedro-Botet, Xavier Pintó

Kardiyoloji Anabilim Dalı

Araştırma sonucu: Dergiye katkı › Makale › bilirkişi

4 Alıntılar (Scopus)

Özet

LDLc levels are associated with increase of cardiovascular risk, and statins are currently used for their control. Nevertheless, a despite of LDLc levels at goal, a residual risk is persistent, commonly associated with persistent lipids modifications (high triglycerides and low HDLc). So, it is necessary to evaluate triglycerides and HDL to assessment cardiovascular risk. Clinical data are consistent with efficacy and safety of combination therapy with statin and other lipid lowering drugs, for instance fenofibrate. Patients with hipertriglyceridemia and low HDLc are the group with most potential improve. In that patients with atherogenic dyslipidemia, the target for therapeutic objectives related with non-HDL-cholesterol is a priority, because non-HDL-cholesterol is considered as a more accuracy measure to assessment cardiovascular risk.

Tercüme edilen katkı başlığı	Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy
Orijinal dil	İspanyolca
Sayfa (başlangıç-bitiş)	87-93
Sayfa sayısı	7
Dergi	Clinica e Investigacion en Arteriosclerosis
Hacim	28
Basın numarası	2
DOI'lar	https://doi.org/10.1016/j.arteri.2015.12.001
Yayın durumu	Yayınlandı - 1 Mar 2016

Belgeye Erişim

10.1016/j.arteri.2015.12.001

Diger dosyalar ve linkler

Link to publication in Scopus

Bundan alıntı yap

Aguiar, C., Alegría, E., Bonnadonna, R. C., Catapano, A. L., Consentido, F., Elisaf, M., Farnier, M., Fierrières, J., Filardi, P. P., Hancu, N., Kayikcioglu, M., Mello e Silva, A., Millán, J., Reiner, Z., Tokgozoglu, L., Valensi, P., Viigimaa, M., Vrablik, M., Zambón, A., ... Pintó, X. (2016). Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato. Clinica e Investigacion en Arteriosclerosis, 28(2), 87-93. https://doi.org/10.1016/j.arteri.2015.12.001

@article{dc3c9d05c8cd4dceb350d327b436f30b,

title = "Consenso sobre tratamiento farmacol{\'o}gico de la dislipidemia aterog{\'e}nica con terapia combinada estatina-fenofibrato",

abstract = "LDLc levels are associated with increase of cardiovascular risk, and statins are currently used for their control. Nevertheless, a despite of LDLc levels at goal, a residual risk is persistent, commonly associated with persistent lipids modifications (high triglycerides and low HDLc). So, it is necessary to evaluate triglycerides and HDL to assessment cardiovascular risk. Clinical data are consistent with efficacy and safety of combination therapy with statin and other lipid lowering drugs, for instance fenofibrate. Patients with hipertriglyceridemia and low HDLc are the group with most potential improve. In that patients with atherogenic dyslipidemia, the target for therapeutic objectives related with non-HDL-cholesterol is a priority, because non-HDL-cholesterol is considered as a more accuracy measure to assessment cardiovascular risk.",

keywords = "Atherogenic dyslipidemia, Lipid lowering combination therapy, Statine-fenofibrate association",

author = "Carlos Aguiar and Eduardo Alegr{\'i}a and Bonnadonna, \{Ricardo C.\} and Catapano, \{Alberico L.\} and Francesco Consentido and Moses Elisaf and Michel Farnier and Jean Fierri{\`e}res and Filardi, \{Pasquale Perronre\} and Nicolae Hancu and Meral Kayikcioglu and \{Mello e Silva\}, Alberto and Jes{\'u}s Mill{\'a}n and Zeljko Reiner and Lale Tokgozoglu and Paul Valensi and Margas Viigimaa and Michal Vrablik and Alberto Zamb{\'o}n and Zamorano, \{Jos{\'e} Luis\} and Roberto Ferrari and Mariano Blasco and {\'A}ngel Brea and {\'A}ngel D{\'i}az and Santos, \{Pedro Gonz{\'a}les\} and Mijares, \{Antonio Hern{\'a}ndez\} and Teresa Mantilla and Juan Pedro-Botet and Xavier Pint{\'o}",

note = "Publisher Copyright: {\textcopyright} 2015 Sociedad Espa{\~n}ola de Arteriosclerosis.",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.arteri.2015.12.001",

language = "İspanyolca",

volume = "28",

pages = "87--93",

journal = "Clinica e Investigacion en Arteriosclerosis",

issn = "0214-9168",

publisher = "Sociedad Espanola de Arteriosclerosis",

number = "2",

}

Aguiar, C, Alegría, E, Bonnadonna, RC, Catapano, AL, Consentido, F, Elisaf, M, Farnier, M, Fierrières, J, Filardi, PP, Hancu, N, Kayikcioglu, M, Mello e Silva, A, Millán, J, Reiner, Z, Tokgozoglu, L, Valensi, P, Viigimaa, M, Vrablik, M, Zambón, A, Zamorano, JL, Ferrari, R, Blasco, M, Brea, Á, Díaz, Á, Santos, PG, Mijares, AH, Mantilla, T, Pedro-Botet, J & Pintó, X 2016, 'Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato', Clinica e Investigacion en Arteriosclerosis, hac. 28, no. 2, pp. 87-93. https://doi.org/10.1016/j.arteri.2015.12.001

TY - JOUR

T1 - Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato

AU - Aguiar, Carlos

AU - Alegría, Eduardo

AU - Bonnadonna, Ricardo C.

AU - Catapano, Alberico L.

AU - Consentido, Francesco

AU - Elisaf, Moses

AU - Farnier, Michel

AU - Fierrières, Jean

AU - Filardi, Pasquale Perronre

AU - Hancu, Nicolae

AU - Kayikcioglu, Meral

AU - Mello e Silva, Alberto

AU - Millán, Jesús

AU - Reiner, Zeljko

AU - Tokgozoglu, Lale

AU - Valensi, Paul

AU - Viigimaa, Margas

AU - Vrablik, Michal

AU - Zambón, Alberto

AU - Zamorano, José Luis

AU - Ferrari, Roberto

AU - Blasco, Mariano

AU - Brea, Ángel

AU - Díaz, Ángel

AU - Santos, Pedro Gonzáles

AU - Mijares, Antonio Hernández

AU - Mantilla, Teresa

AU - Pedro-Botet, Juan

AU - Pintó, Xavier

PY - 2016/3/1

Y1 - 2016/3/1

N2 - LDLc levels are associated with increase of cardiovascular risk, and statins are currently used for their control. Nevertheless, a despite of LDLc levels at goal, a residual risk is persistent, commonly associated with persistent lipids modifications (high triglycerides and low HDLc). So, it is necessary to evaluate triglycerides and HDL to assessment cardiovascular risk. Clinical data are consistent with efficacy and safety of combination therapy with statin and other lipid lowering drugs, for instance fenofibrate. Patients with hipertriglyceridemia and low HDLc are the group with most potential improve. In that patients with atherogenic dyslipidemia, the target for therapeutic objectives related with non-HDL-cholesterol is a priority, because non-HDL-cholesterol is considered as a more accuracy measure to assessment cardiovascular risk.

AB - LDLc levels are associated with increase of cardiovascular risk, and statins are currently used for their control. Nevertheless, a despite of LDLc levels at goal, a residual risk is persistent, commonly associated with persistent lipids modifications (high triglycerides and low HDLc). So, it is necessary to evaluate triglycerides and HDL to assessment cardiovascular risk. Clinical data are consistent with efficacy and safety of combination therapy with statin and other lipid lowering drugs, for instance fenofibrate. Patients with hipertriglyceridemia and low HDLc are the group with most potential improve. In that patients with atherogenic dyslipidemia, the target for therapeutic objectives related with non-HDL-cholesterol is a priority, because non-HDL-cholesterol is considered as a more accuracy measure to assessment cardiovascular risk.

KW - Atherogenic dyslipidemia

KW - Lipid lowering combination therapy

KW - Statine-fenofibrate association

UR - https://www.scopus.com/pages/publications/84955282941

U2 - 10.1016/j.arteri.2015.12.001

DO - 10.1016/j.arteri.2015.12.001

M3 - Makale

C2 - 26811267

AN - SCOPUS:84955282941

SN - 0214-9168

VL - 28

SP - 87

EP - 93

JO - Clinica e Investigacion en Arteriosclerosis

JF - Clinica e Investigacion en Arteriosclerosis

IS - 2

ER -

Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato

Özet

Belgeye Erişim

Diger dosyalar ve linkler

Parmak izi

Bundan alıntı yap